Shares of ADC Therapeutics SA (NYSE:ADCT – Get Free Report) have been given an average rating of “Moderate Buy” by the six ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $8.33.
ADCT has been the subject of a number of research analyst reports. HC Wainwright lowered their target price on ADC Therapeutics from $20.00 to $12.00 in a report on Tuesday, June 20th. Bank of America cut ADC Therapeutics from a “neutral” rating to an “underperform” rating in a research note on Monday, April 24th. Finally, Morgan Stanley decreased their price objective on ADC Therapeutics from $5.00 to $2.00 in a research note on Tuesday, July 11th.
Hedge Funds Weigh In On ADC Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Moneta Group Investment Advisors LLC boosted its holdings in ADC Therapeutics by 12.5% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 21,933 shares of the company’s stock valued at $84,000 after purchasing an additional 2,431 shares in the last quarter. Advisor Group Holdings Inc. lifted its stake in ADC Therapeutics by 1,270.5% in the first quarter. Advisor Group Holdings Inc. now owns 3,248 shares of the company’s stock valued at $47,000 after buying an additional 3,011 shares during the last quarter. Quantbot Technologies LP purchased a new stake in ADC Therapeutics in the second quarter valued at approximately $38,000. Hennion & Walsh Asset Management Inc. lifted its stake in ADC Therapeutics by 14.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 58,869 shares of the company’s stock valued at $226,000 after buying an additional 7,337 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in ADC Therapeutics by 1,253.3% in the third quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock valued at $46,000 after buying an additional 8,773 shares during the last quarter. 70.29% of the stock is owned by institutional investors and hedge funds.
ADC Therapeutics Stock Performance
ADC Therapeutics (NYSE:ADCT – Get Free Report) last announced its earnings results on Tuesday, May 9th. The company reported ($0.74) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.06. ADC Therapeutics had a negative return on equity of 229.20% and a negative net margin of 108.86%. The company had revenue of $18.99 million during the quarter, compared to analysts’ expectations of $20.10 million. As a group, sell-side analysts forecast that ADC Therapeutics will post -2.61 earnings per share for the current year.
ADC Therapeutics Company Profile
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL).
See Also
- Five stocks we like better than ADC Therapeutics
- U.S. Bancorp Shares Rally As Analysts Get Bullish After Q2 Report
- AutoNation Beats Earnings Expectations, Stock Down?
- American Express Hiccups After Earnings, Time To Buy?
- ISRG Stock Sinks After Strong Earnings: Is the Growth Priced In?
- Winners And Losers In The Oilfield Supercycle
Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
